1Dinh P, Harnett P, Piccart-Gebhart MJ, et al. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents [J].Crit Rev Oncol Hematol,2008,67(2) : 103-112.
2Geisler JP, Linnemeier GC, Thomas A J, et al. Extreme drug resistance is eommon after prior exposure to paelitaxel[J]. Gyne col Oncol, 2007,106(3) : 538-540.
3Tinker AV, Gebski V, Fitzharris B, et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG[J]. Gyneeol Oncol,2007,104(3) :647-653.
4Linch M,Stavridi F, Hook J, et al. Experience in a UK cancer centre of weekly paelitaxel in the treatment of relapsed ovarian and primary peritoneal cancer [J]. Gyneeol Oncol, 2008, 109 ( 1 ) : 27-32.
5Ho EA,Soo PL, Allen C, et al. Impact of intraperitoneal sustained delivery of paclitaxel on the expression of P glycoprotein in ovarian tumors[J]. J Control Release, 2007,117 ( 1 ) : 20-27.
6Katsaros D,Oletti MV, Rigauh de la Longrais IA, et al. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma[J]. Ann Oncol, 2005,16 (2) : 300-306.
7Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles[J]. Biomaterials, 2007,28 (12) : 2137-2146.
8Helm CW, Randall-Whitis L, Martin RS 3rd, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma[J]. Gynecol Oncol, 2007, 105 (1) :90-96.
9Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian careinoma[J]. Gynecol Oncol,2007,106(3) :482-487.
10Scholz HS, Tasdemir H, Hunlich T, et al. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer : results and 5-year follow-up [J]. Gynecol Oneol, 2007, 106(3) : 591-595.
二级参考文献13
1J萨姆布鲁克.分子克隆实验指南[M].北京:科学出版社,1992..
2[1]Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis[J]. Am J Pathol. 1995, 146(5): 1029-1039.
3[2]Ueda M, Terai Y, Kumagai K, Ueki K, et al. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells[J]. Gynecol Oncol, 2001, 82(1): 162-166.
4[3]Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization[J]. Am J Pathol, 1998, 153(4): 1249-1256.
5[4]Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction[J]. Proc Natl Acad Sci USA, 1990, 87(18): 7160-7164.
6[5]Fujimoto J, Sakaguchi H, Aoki I, et al. Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers[J]. Br J Cancer, 2001, 85(3): 313-316.
7[6]Fujimoto J, Sakaguchi H, Hirose R, et al. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma[J]. Cancer, 1998, 83(12): 2528-2533.
8[7]Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization[J]. Am J Pathol, 1998, 153(4): 1249-1256.
9[8]Yukita A, Asano M, Okamoto T, et al. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo [J]. Anticancer Res, 2000, 20(1A): 155-160.
10[9]Asano M, Yukita A, Matsumoto T, et al. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo [J]. Hybridoma, 1998, 17(2): 185-190.
9Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer [J]. Crit Rev Oncol Hematol, 2006, 60(2):159-179.
10Fotopoulou C Savatis K. Primary radical surgery in elderly patient s with epithelial ovarian cancer analysis of surgical outcome and long -term survival [J]. Int J Gynecol Cancer, 2010,20 (1):34-40.
